UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000012472
Receipt number R000014601
Scientific Title Imatinib discontinuation for Chronic Myelogenou Leukemia-Chronic Phase with 2 years complete molecular remission.
Date of disclosure of the study information 2013/12/04
Last modified on 2013/12/03 14:19:55

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Imatinib discontinuation for Chronic
Myelogenou Leukemia-Chronic Phase with 2 years complete molecular remission.

Acronym

Delightedly Overcome CML Expert Stop TKI Trial
(DOMEST Trial)

Scientific Title

Imatinib discontinuation for Chronic
Myelogenou Leukemia-Chronic Phase with 2 years complete molecular remission.

Scientific Title:Acronym

Delightedly Overcome CML Expert Stop TKI Trial
(DOMEST Trial)

Region

Japan


Condition

Condition

Chronic Myelogenou Leukemia-Chronic Phase who have maintained complete molecular remission for at least 2 years.

Classification by specialty

Hematology and clinical oncology

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

The purpose of this study is molecular relapse free survival rate after discontinuation of Imatinib in patients with Chronic Myelogenou Leukemia-Chronic Phase who have maintained complete molecular remission for at least 2 years.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2


Developmental phase

Phase II


Assessment

Primary outcomes

Molecular relapse free survival rate after discontinuation of Imatinib at 6 months.

Key secondary outcomes

Molecular relapse free survival rate after discontinuation of Imatinib at 12,24 months.
We assessed previous interferon therapy, sex , sokal risk group and total duration of Imatinib treatment as potential prognostic factors for molecular relapse free survival.
CMR rate and time to CMR of PCR+ patients by PCR screening after dasatinib treatment.
CMR rate and time to CMR of dasatinib treatment after molecular relapse.


Base

Study type

Interventional


Study design

Basic design

Factorial

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Historical

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

3

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Discontinuation of Imatinib in patients with Chronic Myelogenou Leukemia-Chronic Phase who have maintained complete molecular remission for at least 2 years.

Interventions/Control_2

Dasatinib treatment to PCR+ patients by PCR screening.

Interventions/Control_3

Dasatinib treatment to molecular relapse patients during discontinuation Imatinib treatment.

Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

15 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Patients with Chronic Myelogenou Leukemia-Chronic Phase who have maintained complete molecular remission for at least 2 years.
2. ECOG performance status (PS) score 0-2
3. Adequate hepatic, renal and lung function
4. Signed written informed consent

Key exclusion criteria

1. Concurrent malignancy other than CML
2.Women who are pregnant or breastfeeding
3. A serious uncontrolled medical disorder that would impair the ability of the subjects to receive protocol therapy
4.Subjects with clonal evolution

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Shinya Kimura

Organization

Saga Univ, Faculty of Medicine

Division name

Division of Hematology, Respiratory Medicine and Oncology

Zip code


Address

5-1-1 Nabeshima Saga

TEL

0952-34-2353

Email

shkimu@cc.saga-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Shinya Kimura

Organization

DOMEST-Trial Group

Division name

Division of Hematology, Respiratory Medicine and Oncology, Faculty of Medicine, Saga Univ.

Zip code


Address

5-1-1 Nabeshima Saga

TEL

0952-34-2353

Homepage URL


Email

shkimu@cc.saga-u.ac.jp


Sponsor or person

Institute

Epidemiological and Clinical Research Information Network (ECRIN)

Institute

Department

Personal name



Funding Source

Organization

Epidemiological and Clinical Research Information Network (ECRIN)

Organization

Division

Category of Funding Organization

Non profit foundation

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

佐賀大学医学部(佐賀県)Faculty of Medicine, Saga Univ.


Other administrative information

Date of disclosure of the study information

2013 Year 12 Month 04 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2013 Year 10 Month 31 Day

Date of IRB


Anticipated trial start date

2013 Year 12 Month 04 Day

Last follow-up date

2019 Year 04 Month 30 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2013 Year 12 Month 03 Day

Last modified on

2013 Year 12 Month 03 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014601


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name